2009 Biosimilars Drug Pricing 
pharmaphorum
JUNE 12, 2025
Importantly, this type of insight also supports smarter negotiations around drug pricing. In communities where there is only one pharmacy – or none – there is no competition to drive down prices. By identifying these regions, PBMs can better advocate for fair pricing models that reflect real-world access challenges.
pharmaphorum
JUNE 17, 2025
. … So if we can reduce some of the unnecessary cost and time of the six to 15 months toxicity and animal testing period, we can lower barriers to entry, we can lower R&D costs, and we can ideally lower drug prices, which is a big goal for this administration.” Oncology IMUNON at ASCO 2025: Changing the micro-tumour environment i.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Safe Biologics
SEPTEMBER 12, 2023
ASBM & GaBI Webinar on Medicare Price Negotiation Examines Impact on Innovation, Patient Access On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled MEDICARE DRUG PRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines.
Express Pharma
SEPTEMBER 6, 2023
Known as biosimilars, these biopharma products are highly similar to innovator products and have no clinically meaningful dissimilarities, especially in terms of efficacy, safety or quality. Indian pharma players could play a key role in positioning biosimilars as superior products to costly biologics.
pharmaphorum
JUNE 18, 2025
EYs latest Biotech Beyond Borders report acknowledges the seismic changes in the US in the last few months, including cuts to NIH funding , staff reductions at the FDA which could affect its ability to review and approve new products, the threat of tariffs on medicines, and new drug pricing proposals such as Trumps most favoured nation policy.
Expert insights. Personalized for you.
59 
Let's personalize your content